Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial

JAMA

Volumn 280, Issue 8, 1998, Pages 708-713

  Stein, Murray B ^a,e   Liebowitz, Michael R ^b   Lydiard, R Bruce ^c   Pitts, Cornelius D ^d   Bushnell, William ^d   Gergel, Ivan ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Columbia University ^*  (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EJACULATION; FEMALE; GASTROINTESTINAL TOXICITY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL DYSFUNCTION; SINGLE BLIND PROCEDURE; SOCIAL PHOBIA; SOMNOLENCE; TREATMENT OUTCOME;

EID: 0032569245     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.8.708     Document Type: Article

References (48)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association Inc; 1994.
2. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia: comorbidity and morbidity in an epidemiological sample. Arch Gen Psychiatry. 1992;49:282-288.
3. Schneier FR, Heckelman LR, Garfinkel R, et al. Functional impairment in social phobia. J Clin Psychiatry. 1994;55:322-331.
4. Stein MB. How shy is too shy? Lancet. 1996;347: 1131-1132.
5. den Boer JA. Social phobia: epidemiology, recognition, and treatment. BMJ. 1997;315:796-800.
6. Safren SA, Heimberg RG, Brown EJ, Holle C. Quality of life in social phobia. Anxiety. 1997;4:126-133.
7. Hazen AL, Stein MB. Clinical phenomenology and comorbidity. In: Stein MB, ed. Social Phobia: Clinical and Research Perspectives. Washington, DC: American Psychiatric Press Inc; 1995:3-41.
8. Stein MB, Walker JR, Forde DR. Public speaking fears in a community sample: prevalence, impact on functioning, and diagnostic classification. Arch Gen Psychiatry. 1996;53:169-174.
9. Kessler RC, McGonagle KA, Zhao S, et al. Life-time and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
10. Magee WJ, Eaton WW, Wittchen HU, McGonagle KA, Kessler RC. Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry. 1996;53:159-168.
11. Stein MB, Walker JR, Forde DR. Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. Am J Psychiatry. 1994;11:408-412.
12. Offord DR, Boyle MH, Campbell D, et al. One year prevalence of psychiatric disorder in Ontarians 15 to 64 years of age. Can J Psychiatry. 1996;41: 559-563.
13. Kessler RC, Stein MB, Berglund PA. Social phobia subtypes in the National Comorbidity Survey. Am J Psychiatry. 1998;155:613-619.
14. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME-MD 1000 Study. JAMA. 1994;72:1749-1756.
15. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD 1000 Study. JAMA. 1995;274:1511-1517.
16. Fifer SK, Mathias SD, Patrick DL, Mazonson PD, Lubeck DP, Buesching DP. Untreated anxiety among adult primary care patients in a health maintenance organization. Arch Gen Psychiatry. 1994; 51:740-750.
17. Schonfeld WH, Verboncoeur CJ, Fifer SK, Lipschutz RC, Lubeck DP, Buesching DP. The functioning and well-being of patients with unrecognized anxiety disorders and major depressive disorder. J Affect Disord. 1997;43:105-119.
18. Weiller E, Bisserbe JC, Boyer P, Lepine JP, Lecrubier Y. Social phobia in general health care: an unrecognised undertreated disabling disorder. Br J Psychiatry. 1996;168:169-174.
19. Liebowitz MR, Gorman JM, Fyer AJ, et al. Social phobia: a review of a neglected anxiety disorder. Arch Gen Psychiatry. 1985;42:729-736.
20. Antony MM, Barlow DH. Social and specific phobias. In: Tasman A, Kay J, Lieberman JA, eds. Psychiatry. Philadelphia, Pa: WB Saunders; 1997: 1037-1059.
21. Liebowitz MR. Pharmacotherapy of social phobia. J Clin Psychiatry. 1993;54(suppl 12):31-35.
22. Marshall RD, Schneier FR, Fallon BA, Feerick J, Liebowitz MR. Medication therapy for social phobia. J Clin Psychiatry. 1994;44(suppl 6):33-37.
23. Jefferson JW. Social phobia: a pharmacologic treatment overview. J Clin Psychiatry. 1995;56 (suppl 5):18-24.
24. Lydiard RB, Brawman-Mintzer O, Ballenger JC. Recent developments in the psychopharmacology of anxiety disorders. J Consult Clin Psychol. 1996;64:660-668.
25. Davidson JRT, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13:423-428.
26. Katschnig H, Stein M, Buller R, on behalf of the International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci. 1997; 247:71-80.
27. Noyes R, Moroz G, Davidson JRT, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997;17:247-254.
28. Heimberg RG, Juster HR. Cognitive-behavioral treatments: literature review. In: Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, eds. Social Phobia: Diagnosis, Assessment, and Treatment. New York, NY: Guilford; 1995:261-301.
29. Scholing A, Emmelkamp PMG. Treatment of generalized social phobia: results at long-term follow-up. Behav Res Ther. 1996;34:447-452.
30. Taylor S. Meta-analysis of cognitive-behavioral treatments for social phobia. J Behav Ther Exp Psychiatry. 1996;27:1-9.
31. Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med. 1994;97 (suppl 6A):24S-32S.
32. Berk M. Fluoxetine and social phobia [letter]. J Clin Psychiatry. 1995;56:36-37.
33. Black B, Uhde TW, Tancer ME. Fluoxetine for the treatment of social phobia [letter]. J Clin Psychopharmacol. 1992;12:293-295.
34. Ringold AL. Paroxetine efficacy in social phobia [letter]. J Clin Psychiatry. 1994;55:363-364.
35. Schneier FR, Chin SJ, Hollander E, Liebowitz MR. Fluoxetine in social phobia [letter]. J Clin Psychopharmacol. 1992;12:62-64.
36. Sternbach H. Fluoxetine treatment of social phobia [letter]. J Clin Psychopharmacol. 1990;10: 230-231.
37. van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry. 1993;54:27-32.
38. Stein MB, Chartier MJ, Hazen AL, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind, placebo-controlled discontinuation. J Clin Psychopharmacol. 1996;16:218-222.
39. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry. 1995;152:1368-1371.
40. van Vliet IM, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: a double-blind, placebo-controlled study with fluvoxamine. Psychopharmacology. 1994;115:128-134.
41. Liebowitz MR, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry. 1992; 49:290-300.
42. First M, Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-IV - Patient Edition. Washington, DC: American Psychiatric Press; 1995.
43. Liebowitz MR. Social phobia. In: Ban TA, Pichot P, Poldinger W, eds. Modern Problems of Pharmacopsychiatry. New York, NY: Karger; 1987;22:152.
44. Watson P, Friend R. Measurement of social-evaluative anxiety. J Consult Clin Psychol. 1969; 33:448-457.
45. Leon AC, Shear MK, Portera L, Klerman GL. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol. 1992;27:78-82.
46. Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry. 1990;51(suppl 12B):28-33.
47. De Wilde J, Spiers R, Mertens C, Bartholomé F, Schotte G, Leyman S. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand. 1993;87:141-145.
48. Mattick RP, Page A, Lampe L. Cognitive and behavioral aspects. In: Stein MB, ed. Social Phobia: Clinical and Research Perspectives. Washington, DC: American Psychiatric Association; 1995:189-228.